Evaluating the risk of aspiration in elective surgery patients on Semaglutide
Improving Patient Safety for Surgical Patients on Semaglutide: A Gastric Ultrasound Initiative
This study is trying to see if taking Semaglutide affects the risk of having a full stomach in patients scheduled for elective surgery and how the timing of their last dose impacts this.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06420739 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the incidence of 'full stomach' in patients taking Semaglutide who are scheduled for elective surgery. It will investigate how the timing of the last Semaglutide dose affects this risk and develop evidence-based guidelines for managing these patients perioperatively. The study utilizes gastric ultrasound to monitor gastric contents and ensure patient safety during anesthesia. Given the rising use of Semaglutide, understanding its implications for surgical patients is crucial.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older scheduled for elective surgery at Toronto Western Hospital who have been on Semaglutide for at least one month.
Not a fit: Patients who are pregnant or have had previous upper gastrointestinal surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance patient safety protocols for elective surgeries involving patients on Semaglutide.
How similar studies have performed: While there have been concerns raised about the risks associated with Semaglutide in surgical settings, this specific approach to evaluating its impact on aspiration risk is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients scheduled for elective surgery at Toronto Western Hospital 2. Aged ≥ 18 years of age 3. American Society of Anaesthesia physical status classification I to III 4. Patients being treated with Semaglutide for at least 1 month Exclusion Criteria: 1. Current pregnancy evidenced by positive urinary pregnancy test 2. Previous surgery of the upper gastrointestinal tract
Where this trial is running
Toronto, Ontario
- Toronto Western Hospital — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Anahi Perlas — Investigator-Sponsor
- Study coordinator: Anahi Perlas, MD FRCPC
- Email: anahi.perlas@uhn.ca
- Phone: 4166035800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.